Galapagos invests in early pipeline with small molecule partnership

4 January 2024

A significant collaboration agreement has been reached between Belgian biotech Galapagos (Nasdaq: GLPG) and private Californian company BridGene Biosciences.

Following a change of leadership, which saw one of the firm’s original founders Paul Stoffels taking the reins, Galapagos has undertaken a strategic overhaul, focusing on oncology and immunology.

This has come after a period of difficulty, including flagship product Jyseleca (filgotinib) struggling to gain approval in the USA and erstwhile partner Gilead Sciences (Nasdaq: GILD) walking away.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK